AU2002319033B2 - Methods for increasing in vivo efficacy of oligonucleotides and inhibiting inflammation in mammals - Google Patents

Methods for increasing in vivo efficacy of oligonucleotides and inhibiting inflammation in mammals Download PDF

Info

Publication number
AU2002319033B2
AU2002319033B2 AU2002319033A AU2002319033A AU2002319033B2 AU 2002319033 B2 AU2002319033 B2 AU 2002319033B2 AU 2002319033 A AU2002319033 A AU 2002319033A AU 2002319033 A AU2002319033 A AU 2002319033A AU 2002319033 B2 AU2002319033 B2 AU 2002319033B2
Authority
AU
Australia
Prior art keywords
nucleic acid
acid molecule
diseases
group
dap
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002319033A
Other languages
English (en)
Other versions
AU2002319033A1 (en
Inventor
Zoulfia Allakhverdi
Mustapha Allam
Paolo Renzi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmaxis Ltd
Original Assignee
Pharmaxis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmaxis Ltd filed Critical Pharmaxis Ltd
Publication of AU2002319033A1 publication Critical patent/AU2002319033A1/en
Application granted granted Critical
Publication of AU2002319033B2 publication Critical patent/AU2002319033B2/en
Assigned to PHARMAXIS LTD reassignment PHARMAXIS LTD Request for Assignment Assignors: TOPIGEN PHARMACEUTIQUE INC.
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/333—Modified A

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
AU2002319033A 2001-07-06 2002-07-08 Methods for increasing in vivo efficacy of oligonucleotides and inhibiting inflammation in mammals Ceased AU2002319033B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30307101P 2001-07-06 2001-07-06
US60/303,071 2001-07-06
PCT/CA2002/001046 WO2003004511A2 (en) 2001-07-06 2002-07-08 Methods for increasing in vivo efficacy of oligonucleotides and inhibiting inflammation in mammals

Publications (2)

Publication Number Publication Date
AU2002319033A1 AU2002319033A1 (en) 2003-05-22
AU2002319033B2 true AU2002319033B2 (en) 2008-01-10

Family

ID=23170407

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002319033A Ceased AU2002319033B2 (en) 2001-07-06 2002-07-08 Methods for increasing in vivo efficacy of oligonucleotides and inhibiting inflammation in mammals

Country Status (13)

Country Link
US (2) US7745420B2 (enExample)
EP (1) EP1406667B1 (enExample)
JP (1) JP4903984B2 (enExample)
AT (1) ATE386548T1 (enExample)
AU (1) AU2002319033B2 (enExample)
CA (1) CA2451738C (enExample)
DE (1) DE60225141T2 (enExample)
DK (1) DK1406667T3 (enExample)
ES (1) ES2301659T3 (enExample)
MX (1) MXPA04000162A (enExample)
NZ (1) NZ530360A (enExample)
PT (1) PT1406667E (enExample)
WO (1) WO2003004511A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101087623B (zh) * 2004-10-29 2012-09-26 托皮根药品公司 用于治疗变态反应和肿瘤细胞增殖的反义寡核苷酸
US20100184833A1 (en) 2006-08-11 2010-07-22 Prosenta Technologies B.V. Methods and means for treating dna repeat instability associated genetic disorders
ES2639852T3 (es) 2007-10-26 2017-10-30 Academisch Ziekenhuis Leiden Medios y métodos para contrarrestar los trastornos musculares
USRE48468E1 (en) 2007-10-26 2021-03-16 Biomarin Technologies B.V. Means and methods for counteracting muscle disorders
EP2119783A1 (en) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
JP2011519579A (ja) * 2008-05-15 2011-07-14 トピジェン ファーマスーティカルズ インク 炎症および新生細胞増殖の治療のためのオリゴヌクレオチド
WO2010048731A1 (en) * 2008-10-31 2010-05-06 Christopher John Ong Aminoacyl trna-synthetase inhibitors as broad-spectrum immunosuppressive agents
US9622909B2 (en) 2009-02-26 2017-04-18 Advanced Cooling Therapy, Inc. Devices and methods for controlling patient temperature
US9326890B2 (en) 2009-02-26 2016-05-03 Advanced Cooling Therapy, Inc. Devices and methods for controlling patient temperature
US9301871B2 (en) 2009-02-26 2016-04-05 Advanced Cooling Therapy, Inc. Devices and methods for controlling patient temperature
ES2575302T3 (es) * 2009-02-26 2016-06-27 Advanced Cooling Therapy, Inc. Dispositivos para controlar la temperatura del paciente
SG192869A1 (en) * 2011-02-24 2013-09-30 Pharmaxis Ltd Oligonucleotide inhibitors with chimeric backbone and 2-amino-2'-deoxyadenosine
CN118581086A (zh) 2012-01-27 2024-09-03 比奥马林技术公司 用于治疗杜兴型肌营养不良症和贝克型肌营养不良症的具有改善特性的rna调节性寡核苷酸
US9272016B2 (en) * 2012-04-20 2016-03-01 University Of Iowa Research Foundation Methods to enhance RNAi oligonucleotide delivery to respiratory epithelial cells
HUE033431T2 (en) 2012-04-23 2017-11-28 Biomarin Tech Bv RNA modulating oligonucleotides with improved characteristics in the treatment of neuromuscular disorders
FR3057774B1 (fr) * 2016-10-21 2025-11-07 Museum Nat Dhistoire Naturelle Derives de la purine pour leur utilisation dans le traitement ou la prevention de maladies dues a une mutation non-sens

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3337530A (en) * 1965-09-20 1967-08-22 Upjohn Co Dinucleoside 3', 5' -and 2', 5'-phosphates containing one 7-deazapurin riboside moiety
US5856466A (en) * 1990-01-11 1999-01-05 Isis Pharmaceuticals, Inc. Process for the preparation of 2'-O-alkyl purine phosphoramidites
WO1999066037A2 (en) * 1998-06-17 1999-12-23 Recherches Expertises Et Developpement Medicaux Parenz Inc. Antisense oligonucleotides for treating or preventing atopic diseases and neoplastic cell proliferation
WO1999067378A1 (en) * 1998-06-19 1999-12-29 Mcgill University ANTISENSE OLIGONUCLEOTIDE CONSTRUCTS BASED ON β-ARABINOFURANOSE AND ITS ANALOGUES
WO2000012563A1 (en) * 1998-09-01 2000-03-09 Isis Pharmaceuticals, Inc. Improved process for the synthesis of oligonucleotides incorporating 2-aminoadenosine

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01173818A (ja) * 1987-12-28 1989-07-10 Aisin Aw Co Ltd 車両用ナビゲーション装置
US5523205A (en) * 1988-08-02 1996-06-04 Institut Pasteur DNA probes specific for hemolytic listeria
US5112961A (en) * 1990-07-18 1992-05-12 Schering Corporation Dna encoding subunits of a high affinity gm-csf receptor
CA2102224A1 (en) * 1991-04-19 1992-10-20 Toshio Kitamura Human interleukin-3-receptor component
US5872242A (en) 1992-10-05 1999-02-16 Isis Pharmaceuticals, Inc. Antisense oligonucleotide inhibition of ras
GB9301000D0 (en) 1993-01-20 1993-03-10 Glaxo Group Ltd Chemical compounds
US6077668A (en) * 1993-04-15 2000-06-20 University Of Rochester Highly sensitive multimeric nucleic acid probes
EP1102786A4 (en) * 1998-08-03 2002-03-06 Univ East Carolina AGENT COMPRISING ANTISENSE OLIGONUCLEOTIDES WITH LOW ADENOSINE CONTENT, COMPOSITION, KIT AND TREATMENTS
WO2000062736A2 (en) 1999-04-06 2000-10-26 East Carolina University Low adenosine anti-sense oligonucleotide, compositions, kit and method for treatment of airway disorders associated with bronchoconstriction, lung inflammation, allergy(ies) and surfactant depletion

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3337530A (en) * 1965-09-20 1967-08-22 Upjohn Co Dinucleoside 3', 5' -and 2', 5'-phosphates containing one 7-deazapurin riboside moiety
US5856466A (en) * 1990-01-11 1999-01-05 Isis Pharmaceuticals, Inc. Process for the preparation of 2'-O-alkyl purine phosphoramidites
WO1999066037A2 (en) * 1998-06-17 1999-12-23 Recherches Expertises Et Developpement Medicaux Parenz Inc. Antisense oligonucleotides for treating or preventing atopic diseases and neoplastic cell proliferation
WO1999067378A1 (en) * 1998-06-19 1999-12-29 Mcgill University ANTISENSE OLIGONUCLEOTIDE CONSTRUCTS BASED ON β-ARABINOFURANOSE AND ITS ANALOGUES
WO2000012563A1 (en) * 1998-09-01 2000-03-09 Isis Pharmaceuticals, Inc. Improved process for the synthesis of oligonucleotides incorporating 2-aminoadenosine

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
American Journal of Respiratory and Critical Care Medicine, vol. 163, 2001, pages 989-93 *
Antisense Research and Applications, 1993, pages 273-288 *
Antisense Research and Applications, 1998, pages 1-50 *
Biochemistry, vol. 3, no. 7, 1968, pages 932-39 *
Chemical Reviews, vol. 90, no. 4, 1 June 1990, pages 543-584 *
Journal of Medicinal Chemistry, vol. 42, 1999, pages 1625-38 *
Journal of the American Chemical Society, vol. 113, 1991, pages 4313-22 *
Nucleic Acids Research, vol. 26, no. 14, 1998, pages 3350-57 *
Tetrahedron, vol. 52, no. 19, 1996, pages 6759-80 *

Also Published As

Publication number Publication date
EP1406667B1 (en) 2008-02-20
DK1406667T3 (da) 2008-06-16
DE60225141T2 (de) 2009-03-05
US20050032723A1 (en) 2005-02-10
CA2451738C (en) 2013-09-17
WO2003004511A2 (en) 2003-01-16
MXPA04000162A (es) 2006-05-22
JP2004532900A (ja) 2004-10-28
US20100286235A1 (en) 2010-11-11
ATE386548T1 (de) 2008-03-15
WO2003004511A3 (en) 2003-07-10
JP4903984B2 (ja) 2012-03-28
EP1406667A2 (en) 2004-04-14
ES2301659T3 (es) 2008-07-01
CA2451738A1 (en) 2003-01-16
US7745420B2 (en) 2010-06-29
DE60225141D1 (de) 2008-04-03
NZ530360A (en) 2006-01-27
PT1406667E (pt) 2008-05-23

Similar Documents

Publication Publication Date Title
US20100286235A1 (en) Methods for increasing in vivo efficacy of oligonucleotides and inhibiting inflammation in mammals
AU2002319033A1 (en) Methods for increasing in vivo efficacy of oligonucleotides and inhibiting inflammation in mammals
DK2850186T3 (en) COMPOSITIONS AND PROCEDURES FOR MODULATING SMN GENFAMILY EXPRESSION
US6025339A (en) Composition, kit and method for treatment of disorders associated with bronchoconstriction and lung inflammation
CN102099474B (zh) 用于治疗炎症和赘生性细胞增殖的寡核苷酸
US20210317457A1 (en) Antisense oligonucleotide (aso) molecules and uses thereof for coronavirus diseases
CN104583399A (zh) 用于调节血红蛋白基因家族表达的组合物和方法
CN104583402A (zh) 用于调节mecp2表达的组合物和方法
WO1998023294A9 (en) Agent and method of treatment for diseases and conditions associated with respiratory ailments and lung inflammation
TW201919654A (zh) 用於抑制α-ENaC表現之RNAi試劑及使用方法
JP2004532900A5 (enExample)
US12365897B2 (en) RNAi agents for inhibiting expression of mucin 5AC (MUC5AC), compositions thereof, and methods of use
US20030203356A1 (en) RNase L activator-antisense complexes
AU2007252192B2 (en) Oligonucleotides affecting expression of phosphodiesterases
JP7788561B2 (ja) アンチセンスオリゴヌクレオチド及びその使用
RU2416412C2 (ru) Антисмысловые олигонуклеотиды для лечения аллергии и пролиферации неопластических клеток
CN117440817A (zh) 用于抑制晚期糖基化终末产物受体表达的RNAi剂、其组合物和使用方法
CN121022824A (zh) 一种核酸、含有该核酸的组合物与缀合物及用途
OA21427A (en) RNAI agents for inhibiting expression of mucin 5AC (MUC5AC), compositions thereof, and methods of use.
CN117660449A (zh) 核酸、药物组合物与缀合物及用途
TW202128999A (zh) 用於減少spdef表現之化合物及方法

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: PHARMAXIS LTD

Free format text: FORMER OWNER WAS: TOPIGEN PHARMACEUTIQUE INC.

MK14 Patent ceased section 143(a) (annual fees not paid) or expired